Novel HIV gag based protease drug resistance mechanism caused by an increased processing of the NC/p1 cleavage site

被引：0
|
作者：
Nijhuis, M
van Maarseveen, N
Schipper, P
Glass, B
Dulude, D
de Jong, D
Goedegebuure, I
Brakier-Gingras, L
Kraeusslich, HG
Boucher, C
机构：
[1] Univ Utrecht, Med Ctr, Dept Virol, Utrecht, Netherlands
[2] Univ Heidelberg, Dept Virol, D-6900 Heidelberg, Germany
[3] Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada
来源：
ANTIVIRAL THERAPY | 2005年 / 10卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
107
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [1] Novel HIV gag based protease drug resistance mechanism caused by an increased processing of the NC/p1 cleavage site
    Nijhuis, M
    van Maarseveen, N
    Schipper, P
    Glass, B
    Dulude, D
    de Jong, D
    Goedegebuure, I
    Brakier-Gingras, L
    Kraeusslich, H
    Boucher, C
    [J]. ANTIVIRAL THERAPY, 2005, 10 : S117 - S117
  • [2] THE GAG PRECURSOR CONTAINS A SPECIFIC HIV-1 PROTEASE CLEAVAGE SITE BETWEEN THE NC (P7) AND P1 PROTEINS
    WONDRAK, EM
    LOUIS, JM
    DEROCQUIGNY, H
    CHERMANN, JC
    ROQUES, BP
    [J]. FEBS LETTERS, 1993, 333 (1-2) : 21 - 24
  • [3] Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity
    van Maarseveen, Noortje M.
    Andersson, Dan
    Lepsik, Martin
    Fun, Axel
    Schipper, Pauline J.
    de Jong, Dorien
    Boucher, Charles A. B.
    Nijhuis, Monique
    [J]. RETROVIROLOGY, 2012, 9
  • [4] Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity
    Noortje M van Maarseveen
    Dan Andersson
    Martin Lepšík
    Axel Fun
    Pauline J Schipper
    Dorien de Jong
    Charles AB Boucher
    Monique Nijhuis
    [J]. Retrovirology, 9
  • [5] Gag NC/p1 protease resistance mutations can cause selection of additional NC/p1 changes to optimize cleavage efficiency and replicative capacity
    Maarseveen, N. M. Van
    Schipper, P. J.
    De Jong, D.
    Boucher, C. A. B.
    Nijuis, M.
    [J]. ANTIVIRAL THERAPY, 2008, 13 (04) : A52 - A52
  • [6] Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors
    Bally, F
    Martinez, R
    Peters, S
    Sudre, P
    Telenti, A
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (13) : 1209 - 1213
  • [7] New mechanism of HIV resistance: investigating cleavage site mutations in Gag
    Andersson, D.
    Van Maarseveen, N. M.
    Nijhuis, M.
    Konvalinka, J.
    [J]. FEBS JOURNAL, 2009, 276 : 298 - 298
  • [8] HIV p7/p1 and p1/p6-gag cleavage site mutations are associated with specific PR mutations and PI resistance profiles.
    Verheyen, J.
    Litau, E.
    Sing, T.
    Schuldenzucker, U.
    Däumer, M.
    Oette, M.
    Lengauer, T.
    Hoffmann, D.
    Pfister, H.
    Kaiser, R.
    [J]. ANTIVIRAL THERAPY, 2006, 11 (05) : S65 - S65
  • [9] Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 gag cleavage site in drug resistance and replication fitness
    Brann, Terrence W.
    Dewar, Robin L.
    Jiang, Min-Kan
    Shah, Akram
    Nagashima, Kunio
    Metcalf, Julia A.
    Falloon, Judith
    Lane, H. Clifford
    Imamichi, Tomozumi
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (12) : 6136 - 6145
  • [10] Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) gag p7NC and the C-cleavage site impact Gag-Pol processing by HIV-1 protease
    Goodenow, MM
    Bloom, G
    Rose, SL
    Pomeroy, SM
    O'Brien, PO
    Perez, EE
    Sleasman, JW
    Dunn, BM
    [J]. VIROLOGY, 2002, 292 (01) : 137 - 149
12345